New Cousteau-Linked...
Health Care: Drugs
ARCA biopharma Inc. (ABIO: NASDAQ)
$0.48 -0.02 | -3.81%
06/04/12 - 01:42 PM ET
Company Cash Flow
| Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -5.36M | -8.42M | -9.14M | -29.92M |
| Operating Gains/Losses | -1.98M | -267.00K | -25.24M | -8.00K |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | 0.00 | 0.00 | 0.00 | 147.00K |
| (Increase) Decrease in Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Current Assets | 14.00K | 58.00K | 2.81M | 1.15M |
| (Decrease) Increase In Payables | -128.00K | -145.00K | -2.46M | -1.04M |
| (Decrease) Increase In Other Current Liabilities | -220.00K | -316.00K | -20.45M | -20.23M |
| (Increase) Decrease In Other Working Capital | -187.00K | -30.00K | 6.98M | -8.30M |
| Other Non-Cash Items | 308.00K | 458.00K | 5.32M | 9.41M |
| Net Cash From Continuing Operations | -6.96M | -8.32M | -41.73M | -46.51M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -6.96M | -8.32M | -41.73M | -46.51M |
| Sale of Property, Plant & Equipment | 25.00K | 6.00K | 322.00K | 0.00 |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 0.00 | 263.00K | 15.11M | 0.00 |
| Purchases of Property, Plant & Equipment | -19.00K | -4.00K | -185.00K | -222.00K |
| Acquisitions | 0.00 | 0.00 | 30.39M | 0.00 |
| Purchases of Short-Term Investments | 0.00 | 0.00 | 0.00 | -44.61M |
| Other Cash from Investing Activities | 2.00M | 0.00 | 0.00 | 18.00K |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | 2.01M | 265.00K | 45.64M | 50.18M |
| Issuance of Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 4.73M | 7.66M | 114.00K | 201.00K |
| Repayment of Long-Term Debt | 0.00 | 0.00 | -4.00M | -46.00K |
| Repurchase of Capital Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | -855.00K | -338.00K | 0.00 | 0.00 |
| Net Cash From Financing Activities | 3.87M | 7.32M | -3.89M | 155.00K |
| Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Change in Cash & Cash Equivalents | -1.08M | -738.00K | 23.00K | 3.83M |
Portfolios with ABIO
- Portfolio NameUser Type
- Userbuddy62370 Portfolio 1
- UserKumaran
- UserSUPRATRADE NEW-BUY LIST-240...
Latest ABIO Headlines from TheStreet
- InfoLogix, Netlist: Midday Volume Plays 05.17.10 | 01:05 pm
- Arca BioPharma Patent Deja Vu: BioBuzz 03.29.10 | 06:03 am
- Sirius XM, ARCA biopharma: Early Volume Plays 03.26.10 | 09:03 am
- Brazilian Telecom, Agria: Midday Volume Plays 11.24.09 | 01:11 pm
- ARCA, FortuNet: Midday Volume Plays 11.23.09 | 01:11 pm
- Funds Sell $4M Worth of Pain Therapeutics 06.11.09 | 09:06 am
- Ford, Deere, Cisco Systems Are Big Movers 06.01.09 | 05:06 pm
- FDA Wants ARCA To Run More Tests On Heart Drug 06.01.09 | 11:06 am
- The Second Dendreon Wave
05.18.09 | 02:05 pm
Press Releases for ABIO
- GencaroTM's Norepinephrine Lowering Likely Contributes To Its Effect In Atrial Fibrillation Prevention - Business Wire 03.26.12 | 12:03 pm
- GencaroTM Atrial Fibrillation Data Selected For Presentation At American College Of Cardiology 61st Annual Scientific Session & Expo - Business Wire 03.20.12 | 08:03 am
- ARCA Biopharma Announces Additional Patent Issued For Methods For Treatment With Bucindolol Based On Genotype Of Patient - Business Wire 01.19.12 | 08:01 am
- CEO Of ARCA Biopharma To Speak On Use Of Biomarkers And Implications Of Personalized Medicine At New Paradigms Conference On January 12, 2012 - Business Wire 01.05.12 | 08:01 am
- Dr. Michael Bristow, CEO, ARCA Biopharma (Photo: Business Wire) - Business Wire 12.30.11 | 08:12 am
- ARCA Biopharma Announces Private Placement Of $1.75 Million With Institutional Investors - Business Wire 12.22.11 | 08:12 am
- Kaplan Meier Curves By Beta-1 389 Arg/Gly Polymorphism. (Graphic: Business Wire) - Business Wire 11.16.11 | 11:11 am
- Dr. Michael Bristow, CEO, ARCA Biopharma (Photo: Business Wire) - Business Wire 11.11.11 | 08:11 am
- Two GencaroTM Atrial Fibrillation Abstracts Accepted For Presentation At The American Heart Association Scientific Sessions 2011 - Business Wire 08.10.11 | 08:08 am
- ARCA Biopharma Announces Planned Expansion Of Gencaro Development To Atrial Fibrillation - Business Wire 05.26.11 | 08:05 am
Partner Headlines for ABIO
- Will the Next Apple or Google Be Found Among These Micro Caps? - Seeking Alpha 08.18.11 | 09:08 am
- Top Percentage Gainers and Losers as of 2pm 05/13/11 (ABIO, GFRE, DDS, APL, DF, VRML, DAR, SWSH, ONTY, GS, RMBS, LPHI, GGS, CA, NVDA, IMRS, MNTX, MPG, GTY) - Benzinga 05.13.11 | 02:05 pm
- Morning Market Movers (ABIO, LBIX, CGNX, AEIS) - Benzinga 05.03.11 | 09:05 am
- UPDATE 1-Arca reaches agreement with FDA on heart-drug study - Reuters 05.17.10 | 09:05 am
- UPDATE 1-ARCA gets U.S. patent related to heart drug; shrs soar - Reuters 03.26.10 | 10:03 am
